Exchange: NYSE·Updated 07:30 PM EDT

HAE News

News
all
press releases
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Zacks
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Zacks
More News
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Zacks
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.
Stocktwits
Haemonetics Stock Hits 52-Week High - Here's Why
Haemonetics stock hits a new 52-week high after CSL Plasma outlines a sweeping rollout of its technology across existing U.S. centers.read more...
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock moved upwardsread more...
Benzinga
PAHC vs. HAE: Which Stock Is the Better Value Option?
PAHC vs. HAE: Which Stock Is the Better Value Option?
Zacks
Haemonetics Q1 2027 Earnings Call Transcript
Haemonetics (NYSE:HAE) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access toread more...
Benzinga
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026 Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026PR NewswireBOSTON, Sept. 30, 2026BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE...
PR Newswire

Advertisement|Remove ads.